Chapter review

Fitzgerald PMHNP board review. ch18. Disorders Revealed by the Cardiac Exam. This is drive 3 of 4. When I say Pause. Answer. wait, then I will give the answer. New section. When to stop the drug, get an ECG, or refer — best next step. Topic. Citalopram Safety Thresholds. Bottom Line. * **citalopram** carries a maximum FDA daily dose ceiling of 40 mg for adults under age 60 due to dose-dependent **QTc prolongation**. * **citalopram** maximum daily dose is 20 mg for adults aged 60 and older, patients with hepatic impairment, CYP2C19 poor metabolizers, or those taking CYP2C19 inhibitors. * QTc interval greater than 500 ms or an increase greater than 60 ms from baseline requires immediate discontinuation of **citalopram** and urgent cardiac evaluation. * **First-line** action prior to initiating **citalopram** in patients with cardiac risk factors, or upon presentation of syncope or palpitations, is ordering a 12-lead **ECG** and checking serum potassium and magnesium levels. * Electrolyte abnormalities, specifically **hypokalemia** and **hypomagnesemia**, significantly increase the risk of Torsades de Pointes when combined with **citalopram**. * **escitalopram** has a lower overall risk of QTc prolongation than **citalopram**, with maximum daily thresholds of 20 mg in younger adults and 10 mg in adults aged 60 and older. * **Board trap**: Selecting a dose increase above 20 mg daily for an older adult with unmanaged depression is a major safety violation on national board exams. Citalopram Safety Thresholds and Clinical Management. Dosing Caps and Cardiac Physiology. **citalopram** is a selective serotonin reuptake inhibitor (SSRI) with specific prescribing restrictions driven by cardiovascular toxicity. The FDA issued a drug safety communication establishing strict daily dose caps because higher exposure causes dose-dependent **QTc prolongation**. This electrical delay in ventricular repolarization predisposes patients to polymorphic ventricular tachycardia, also known as Torsades de Pointes, which can degenerate into fatal ventricular fibrillation. For adults under 60 years of age without hepatic or metabolic impairments, the absolute maximum dose of **citalopram** is 40 mg daily. For patients aged 60 and older, individuals with liver impairment, known CYP2C19 poor metabolizers, or those taking co-administered CYP2C19 inhibitors such as cimetidine, the maximum ceiling is 20 mg daily. QTc Monitoring and Actionable Thresholds. A normal QTc interval is generally less than 450 ms in males and less than 470 ms in females. When monitoring a patient on **citalopram**, specific numbers dictate clinical intervention: * **Safety alert**: A baseline 12-lead **ECG** should be obtained before starting **citalopram** in patients with congestive heart failure, bradyarrhythmias, a history of long QTc syndrome, or concurrent use of other QTc-prolonging psychotropics such as **thioridazine**, **ziprasidone**, or **haloperidol**. * **Safety alert**: If the post-treatment QTc interval exceeds 500 ms, or if the QTc interval prolongs by more than 60 ms from baseline, the PMHNP must immediately discontinue **citalopram**, evaluate serum electrolytes, and order a cardiology consultation. * **First-line**: The **first-line** intervention for any patient taking **citalopram** who reports new-onset syncope, presyncope, severe dizziness, or chest palpitations is obtaining an emergency **ECG** and drawing a basic metabolic panel (**BMP**) with magnesium. Comparison of SSRI Cardiac Risk Profiles. When evaluating cardiac safety across antidepressant options, SSRIs fall along a spectrum of QTc prolongation risk: * High risk: **citalopram** possesses the highest dose-dependent QTc prolongation risk among SSRIs, requiring strict 20 mg and 40 mg caps. * Moderate risk: **escitalopram** causes QTc prolongation at higher doses, capped at 20 mg daily for adults and 10 mg daily for geriatric patients. * Low risk: **sertraline**, **fluoxetine**, and **paroxetine** carry minimal QTc risk at standard therapeutic doses, making **sertraline** a preferred **first-line** SSRI in patients with complex cardiovascular disease or post-myocardial infarction. Common Board Traps. * **Board trap**: Test stems often present a 65-year-old patient taking **citalopram** 20 mg daily whose PHQ-9 score shows persistent depressive symptoms. Option choices will tempt you to increase the dose to 40 mg daily. This is incorrect. The correct answer is to maintain 20 mg and either switch to an alternative agent like **sertraline** or augment treatment, because 20 mg is the absolute geriatric safety limit. * **Board trap**: Stems may describe a patient on **citalopram** who develops diarrhea or takes diuretics, leading to low potassium. Test-writers want you to recognize that **hypokalemia** and **hypomagnesemia** amplify QTc prolongation into Torsades de Pointes. Correcting electrolytes is required alongside cardiac monitoring. Board-Style Practice Question. Question 1. A 66-year-old male with major depressive disorder and a history of hypertension presents for a follow-up visit. He has been taking **citalopram** 20 mg daily for 6 weeks with partial symptom reduction. He reports no chest pain, shortness of breath, or palpitations, but his PHQ-9 score remains elevated at 14. His current medications include hydrochlorothiazide. Which of the following is the most appropriate next step in management? A) Increase **citalopram** to 40 mg daily B) Switch **citalopram** to **sertraline** 50 mg daily and order a basic metabolic panel C) Increase **citalopram** to 30 mg daily and recheck in 2 weeks D) Add **ziprasidone** 20 mg twice daily with meals Pause. Answer: B. * **Best answer**: B * **Why it is correct**: In adults aged 60 and older, 20 mg daily is the maximum FDA recommended dose for **citalopram** due to the elevated risk of dose-dependent **QTc prolongation** and sudden cardiac death. Because the patient is also taking a thiazide diuretic, checking a basic metabolic panel to rule out **hypokalemia** and transitioning to a cardiac-safe alternative like **sertraline** is the most appropriate clinical decision. * **Why the other choices are wrong**: * A: Incorrect because increasing **citalopram** to 40 mg daily in a 66-year-old patient exceeds the maximum recommended safety threshold of 20 mg daily. * C: Incorrect because 30 mg daily exceeds the maximum 20 mg daily safety limit for geriatric patients. * D: Incorrect because adding **ziprasidone**, an antipsychotic with a significant QTc-prolonging profile, alongside **citalopram** in a patient on diuretics creates an additive arrhythmia risk. * **Test-taking pearl**: Memorize the age 60 cutoff for **citalopram**. Under age 60, the ceiling is 40 mg daily. At age 60 or older, the ceiling is 20 mg daily. Never choose a dose above 20 mg for an older adult on board exams. 💡 **Next Study Step**: Would you like to review other cardiovascular medical mimics or explore **lithium** ECG baseline requirements next? Next. Topic. Medical Monitoring Intervals. Source Availability Note. Fitzgerald Chapter 18 as a standalone chapter is not printed in the provided review scans, which cover Chapters 1 through 16. However, the exact cardiac monitoring intervals, ECG rules, drug discontinuation thresholds, and referral criteria for psychotropics are fully detailed across Fitzgerald Chapters 2, 8, 9, 10, and 14. The following review synthesizes these exact Fitzgerald source facts. Bottom Line Summary. * Obtain a baseline 12-lead ECG before starting tricyclic antidepressants like amitriptyline or imipramine, prior to lithium initiation in patients over 40 or with cardiac history, and when combining QTc-prolonging psychotropics. * Cap citalopram at a maximum daily dose of 20 mg in adults aged 60 and older, as well as in poor CYP2C19 metabolizers, due to dose-dependent QTc prolongation and risk of Torsades de Pointes. * Discontinue the offending psychotropic immediately, obtain an emergent 12-lead ECG, check serum potassium and magnesium levels, and refer for emergency medical evaluation if the QTc interval exceeds 500 milliseconds or increases by more than 60 milliseconds from baseline. * Monitor clozapine closely during the first 4 to 6 weeks of initiation for black box signs of myocarditis and cardiomyopathy. Immediately discontinue clozapine and order an urgent troponin, CRP, and ECG if the patient develops unexplained chest pain, dyspnea, tachypnea, fever, or tachycardia. * Baseline metabolic monitoring for second-generation antipsychotics requires measuring weight, body mass index, waist circumference, blood pressure, fasting plasma glucose, and lipid panel. Recheck fasting glucose and lipids at 12 weeks, then annually. * Screen personal and family cardiac history, baseline blood pressure, and heart rate prior to initiating stimulants like methylphenidate or amphetamine mixtures to rule out structural heart defects and sudden cardiac death risk. * Rule out cardiovascular medical mimics such as myocardial infarction, pulmonary embolism, pheochromocytoma, and arrhythmias prior to diagnosing a primary anxiety disorder when a patient presents with new-onset autonomic hyperarousal. High-Yield Concept Map and Spoken Clinical Teaching. Baseline ECG and QTc Prolongation Rules. Safety alert: QTc prolongation increases the risk of Torsades de Pointes, a fatal ventricular arrhythmia. Normal QTc intervals are under 450 milliseconds for men and under 470 milliseconds for women. First-line management: Obtain a baseline 12-lead ECG prior to starting tricyclic antidepressants, ziprasidone, or when initiating citalopram in patients with underlying cardiac conditions. If the baseline QTc is normal, repeat the ECG after reaching steady-state therapeutic dosing or when adding another QTc-prolonging agent. When to stop the drug, get an ECG, or refer: Discontinue the drug immediately, obtain a stat 12-lead ECG, check serum potassium and magnesium, and refer to cardiology if the QTc exceeds 500 milliseconds or increases by more than 60 milliseconds above baseline. Board trap: Do not increase the dose of citalopram above 20 mg daily in adults over 60 years old. Selecting a dose of 40 mg in an older adult is a classic board distractor that increases cardiac risk without providing clinical benefit. Clozapine Cardiac Monitoring and Emergency Discontinuation. Safety alert: Clozapine carries black box warnings for fatal myocarditis and cardiomyopathy, with the highest risk occurring during the first 4 to 6 weeks of treatment. First-line management: Prior to clozapine initiation, obtain a baseline ECG, absolute neutrophil count, baseline troponin, and C-reactive protein. When to stop the drug, get an ECG, or refer: Immediately discontinue clozapine and refer the patient for emergency medical evaluation if they report chest pain, shortness of breath, rapid breathing, fever, or persistent tachycardia. Order an urgent troponin, C-reactive protein, and 12-lead ECG. Do not restart clozapine if myocarditis or cardiomyopathy is confirmed. Board trap: Confusing clozapine-induced myocarditis with a viral upper respiratory infection or benign flu-like illness. Ignoring early cardiac symptoms like fever and tachycardia during the first month of clozapine therapy can lead to fatal heart failure. Metabolic and Endocrine Monitoring Intervals for Antipsychotics. Safety alert: Second-generation antipsychotics, particularly olanzapine and clozapine, carry high risks for weight gain, type 2 diabetes mellitus, and dyslipidemia. First-line management: At baseline, obtain personal and family history, weight, body mass index, waist circumference, blood pressure, fasting plasma glucose, and fasting lipid panel. Recheck weight at every visit for the first 3 months, then quarterly. Recheck fasting plasma glucose and lipid panel at 12 weeks after initiation, and then annually thereafter. When to stop the drug, get an ECG, or refer: Switch to a metabolically neutral second-generation antipsychotic, such as aripiprazole, ziprasidone, or lurasidone, if the patient develops significant metabolic syndrome, rapid weight gain, or uncontrolled hyperglycemia. Board trap: Waiting a full year to recheck lab work after starting olanzapine. The standard protocol requires rechecking fasting glucose and lipids at 12 weeks to catch early metabolic disruption. Lithium Cardiac and Organ System Monitoring. Safety alert: Lithium can cause sinus node dysfunction, flattened T waves, hypothyroidism, and renal impairment. Toxicity occurs when serum levels exceed 1.5 mEq/L. First-line management: Obtain baseline 12-lead ECG (especially in patients over 40 or with cardiac disease), renal function tests including eGFR and serum creatinine, thyroid-stimulating hormone, serum electrolytes, and pregnancy testing. Monitoring intervals: Draw serum lithium levels 12 hours post-dose (trough level) 5 to 7 days after initiation or dose changes. Once stable, monitor lithium levels, eGFR, serum creatinine, and TSH every 6 to 12 months. When to stop the drug, get an ECG, or refer: Withhold lithium, check stat serum lithium level, eGFR, electrolytes, and 12-lead ECG, and refer for emergency care if the patient exhibits coarse hand tremor, dysarthria, ataxia, confusion, or persistent vomiting. Board trap: Relying on serum creatinine alone to assess renal function in an older adult on lithium. Serum creatinine can remain artificially normal due to age-related muscle loss even when eGFR is significantly reduced. Always check eGFR. Stimulant Cardiac Screening in Pediatric and Adult ADHD. Safety alert: Central nervous system stimulants can elevate heart rate and blood pressure, posing risks for patients with occult structural cardiac abnormalities. First-line management: Perform a thorough personal and family cardiovascular history screening for unexplained syncope, exertional chest pain, arrhythmias, or premature sudden cardiac death under age 40. Measure baseline blood pressure and heart rate. When to stop the drug, get an ECG, or refer: Obtain a 12-lead ECG and refer to pediatric or adult cardiology prior to initiating stimulants if the screening uncovers a positive family history of sudden cardiac death or personal cardiac symptoms. Discontinue stimulant therapy if exertional chest pain or syncope occurs during treatment. Board trap: Ordering a routine screening ECG for every healthy child before starting methylphenidate without any cardiac risk factors. A routine ECG is not indicated unless personal or family cardiac risk factors are identified during history taking. Compare and Distinguish: High-Yield Contrast Blocks. QTc Prolongation vs. Clozapine Myocarditis. * Think QTc Prolongation when: Asymptomatic ECG finding or sudden syncope linked to citalopram, tricyclic antidepressants, or ziprasidone. * Think Clozapine Myocarditis when: Symptomatic clinical presentation with chest pain, dyspnea, fever, and tachycardia within the first 4 to 6 weeks of clozapine therapy. * Priority difference: QTc prolongation requires monitoring ECG intervals and stopping the drug if QTc exceeds 500 milliseconds. Clozapine myocarditis requires immediate drug cessation, emergency department referral, and measuring cardiac inflammatory markers like troponin and CRP. * Boards are testing: Recognizing which drug causes silent arrhythmia risk versus active cardiac tissue inflammation. Metabolic Monitoring vs. Renal/Thyroid Monitoring. * Think Metabolic Monitoring when: Prescribing second-generation antipsychotics like olanzapine, quetiapine, or clozapine. Recheck glucose and lipids at 12 weeks, then annually. * Think Renal and Thyroid Monitoring when: Prescribing lithium. Check baseline eGFR, serum creatinine, and TSH, then recheck every 6 to 12 months. * Priority difference: Metabolic risk drives cardiovascular disease over years, whereas lithium toxicity or renal clearance decline can occur rapidly with dehydration or drug interactions. * Boards are testing: Selecting the correct baseline and follow-up lab panel for specific drug classes. Board Practice Questions and Vignette Dissection. Question 1. A 68-year-old female with a history of major depressive disorder is being evaluated for medication adjustment. She is currently taking citalopram 20 mg daily. Her depression remains partially treated, and her family asks if her dose can be increased to 40 mg daily. She has a history of mild hypertension treated with hydrochlorothiazide. Which of the following is the most appropriate next step for the PMHNP? A) Increase citalopram to 40 mg daily and recheck blood pressure in 2 weeks. B) Maintain citalopram at 20 mg daily and augment with evidence-based psychotherapy or a non-SSRI antidepressant. C) Discontinue citalopram immediately and order a stat echocardiogram. D) Increase citalopram to 30 mg daily and obtain a routine serum citalopram level. Pause. Answer: B. Why it is correct: Citalopram carries a specific FDA warning and dose cap of 20 mg daily in adults aged 60 and older due to the risk of dose-dependent QTc prolongation and Torsades de Pointes. Augmenting with psychotherapy or switching/adding an alternative agent is the safest evidence-based approach. Why the other choices are wrong: - A: Increasing citalopram to 40 mg daily in an adult over 60 exceeds the maximum recommended safety limit and increases cardiac risk. - C: Immediate discontinuation and an echocardiogram are unnecessary because 20 mg is a safe dose and the patient has no acute cardiac symptoms. - D: Citalopram levels are not routinely measured, and titrating above 20 mg daily in an older adult violates national safety guidelines. Test-taking pearl: Remember the age cutoff of 60 for citalopram. The maximum dose is 20 mg daily for older adults, poor CYP2C19 metabolizers, or patients taking citalopram with cimetidine. Concept tested: Citalopram dosing limits and QTc prolongation safety in older adults. Question 2. A 32-year-old male with treatment-resistant schizophrenia was initiated on clozapine 3 weeks ago. Today he presents for a routine visit complaining of progressive shortness of breath, low-grade fever of 100.8 degrees Fahrenheit, fatigue, and chest tightness when walking up stairs. His vital signs reveal a heart rate of 118 beats per minute and blood pressure of 110/72 mmHg. What is the most appropriate immediate action by the PMHNP? A) Reassure the patient that flu-like symptoms are common during clozapine titration and continue the current dose. B) Order an urgent complete blood count with differential to evaluate for agranulocytosis. C) Discontinue clozapine immediately, order an urgent 12-lead ECG, troponin, and C-reactive protein, and refer for emergency medical evaluation. D) Reduce the clozapine dose by half and prescribe an oral antibiotic for suspected community-acquired pneumonia. Pause. Answer: C. Why it is correct: Unexplained fever, tachycardia, dyspnea, and chest pain within the first 4 to 6 weeks of clozapine initiation strongly suggest clozapine-induced myocarditis. This is a life-threatening black box emergency requiring immediate clozapine discontinuation, urgent cardiac workup including troponin and CRP, and emergency referral. Why the other choices are wrong: - A: Dismissing these symptoms as benign flu-like responses can result in fatal heart failure or cardiac arrest. - B: Checking the complete blood count addresses neutropenia risk but fails to address the immediate, life-threatening cardiac symptoms of myocarditis. - D: Decreasing the dose or giving antibiotics without stopping clozapine delays critical emergency evaluation for cardiotoxicity. Test-taking pearl: Tachycardia out of proportion to fever combined with dyspnea and chest pain during early clozapine therapy means myocarditis until proven otherwise. Immediately stop the drug and send the patient to the emergency department. Concept tested: Recognizing clozapine-induced myocarditis and managing psychiatric emergencies. Question 3. A 45-year-old female with bipolar I disorder is being evaluated prior to initiating lithium therapy. She has no personal history of cardiovascular disease. Which baseline laboratory and diagnostic workup is required prior to starting lithium? A) Baseline ECG, eGFR, serum creatinine, TSH, serum electrolytes, and pregnancy test. B) Baseline lipid panel, hemoglobin A1C, liver function tests, and brain MRI. C) Baseline serum lithium level, chest X-ray, and 24-hour Holter monitor. D) Baseline urine drug screen, complete blood count with differential, and total bilirubin. Pause. Answer: A. Why it is correct: Comprehensive baseline evaluation prior to lithium includes a 12-lead ECG (to screen for cardiac conduction defects like sinus node dysfunction), renal function tests (eGFR and serum creatinine), thyroid panel (TSH), serum electrolytes, and a pregnancy test due to teratogenic risks. Why the other choices are wrong: - B: Lipid panel and hemoglobin A1C are essential for second-generation antipsychotics, not primary baselines for lithium. - C: A serum lithium level cannot be drawn prior to starting the drug, and Holter monitoring is not a routine baseline requirement. - D: Total bilirubin and chest X-rays are not standard baseline requirements for lithium initiation. Test-taking pearl: Link lithium baseline workup to the organs it affects: kidneys (eGFR/creatinine), thyroid (TSH), heart (ECG), and fetus (pregnancy test). Concept tested: Baseline medical and laboratory monitoring for lithium. Active Recall Checkpoints. 1. What specific QTc interval threshold in milliseconds requires immediate drug discontinuation and emergency referral? 2. What is the maximum recommended daily dose of citalopram in an adult aged 65? 3. Within what time frame after initiating a second-generation antipsychotic should fasting plasma glucose and lipid panels be rechecked? 4. What four baseline lab and diagnostic tests must be obtained before initiating lithium? 5. What clinical symptoms during the first month of clozapine therapy should trigger immediate concern for myocarditis? Next Best Study Step. Review Fitzgerald Chapter 2 (Select Specialty Topics) for comprehensive laboratory interpretation, cytochrome P450 isoenzyme interactions, and hepatic monitoring in psychiatric practice. This closes knowledge gaps in drug metabolism and prevents misinterpreting organ system side effects on board exams. 💡 Would you like to drill a 5-question active recall quiz on Fitzgerald Chapter 2 laboratory monitoring and CYP450 drug interactions next? Next. New section. Exam clue patterns and look-alike cardiac vs anxiety presentations. Topic. Medical Mimics of Panic and Anxiety. Source Notice. Fitzgerald Chapter 18 (**Disorders Revealed by the Cardiac Exam**) is not contained in the provided notebook materials [1, 2]. The Fitzgerald board review sources in this notebook cover introductory board prep, exam blueprints, and Chapters 1 through 16 [2-4]. However, the introductory Fitzgerald review sources explicitly cover **cardiovascular** system integration, medical rule-out principles, and health promotion across national certification domain blueprints [5-8]. The high-yield exam principles and practice items below are grounded strictly in the provided Fitzgerald sources [3, 4, 9-15]. Bottom Line Summary. * The ANCC exam consists of 175 total questions (150 scored, 25 unscored pretest) with a 3.5-hour time limit [3, 16]. * The AANPCB exam consists of 150 total questions (135 scored, 15 unscored pretest) with a 3.0-hour time limit [4, 17]. * Both exams integrate non-psychiatric body systems, requiring candidates to evaluate the **cardiovascular** and **endocrine** systems alongside psychiatric presentations [5, 7]. * The primary healthcare rule dictates intervening at the lowest level of prevention possible [18, 19]. * **Primary prevention** prevents health problems before they occur, such as administering the **influenza vaccine** or counseling on safety [9, 11, 20]. * **Secondary prevention** detects disease in an early, asymptomatic state through screening, such as administering the **PHQ-9** or checking a **lipid profile** [10, 12, 20, 21]. * **Tertiary prevention** manages established disease to minimize complications, such as adjusting a **lithium** level or facilitating an **EAP** return-to-work plan [10, 14, 15, 22, 23]. * Age distribution on the AANPCB exam focuses heavily on **adult** (50%) and **older adult** (20%) populations [24, 25]. Clinical Exam Clues and Prevention Frameworks. Core Exam Architecture. National board certification evaluates whether an examinee possesses the entry-level knowledge and clinical decision-making skills to practice as a safe nurse practitioner [26, 27]. The ANCC and AANPCB exams use integrated testing, mixing diagnoses, age groups, and physical body systems randomly throughout the exam [17, 28]. **Safety alert**: Questions testing physical assessment skills will incorporate secondary classifications [3, 5]. Candidates must recognize **cardiovascular** and **endocrine** mimics or drug side effects before attributing symptoms solely to a primary psychiatric disorder [5, 7]. Levels of Prevention Framework. **First-line**: Always select the lowest applicable level of prevention when evaluating health promotion items [18, 19]. 1. **Primary prevention**: Focuses on preventing health problems in healthy populations [9, 20]. * Examples include **influenza vaccine** administration, safety counseling, physical activity teaching, and home lighting interventions [9, 11-13, 20, 21]. 2. **Secondary prevention**: Focuses on early detection through screening in preclinical or asymptomatic states [10, 20]. * Examples include **blood pressure checks**, **mammography**, **lipid profile** monitoring, **PHQ-9** administration, and screening for **abuse** [10, 12, 13, 20, 21, 29]. 3. **Tertiary prevention**: Focuses on minimizing target organ damage and negative outcomes in established illness [10, 22]. * Examples include **lithium** dosage adjustments, **EAP** return-to-work support following hospitalization, and psychoeducation for families of individuals with severe mental illness [10, 14, 15, 22, 23, 29]. **Board trap**: Do not confuse diagnostic screening with tertiary disease management [10, 20, 22]. Administering a screening scale like the **PHQ-9** to detect unknown depression is **secondary prevention**, whereas adjusting psychotropic medications for known, established **major depressive disorder** or **bipolar disorder** is **tertiary prevention** [10, 13, 15, 20, 23, 29]. Sample Practice Questions. Question 1. In a 46-year-old woman with **bipolar disorder**, counseling about reducing risk for sexually transmitted infection is an example of which level of prevention? * A. Primary prevention * B. Secondary prevention * C. Tertiary prevention * D. Anticipatory guidance Pause. Answer: A. **Why it is correct**: Counseling to prevent disease before it occurs represents **primary prevention** [9, 22]. **Why the other choices are wrong**: * A. Correct. * B. Incorrect because secondary prevention involves screening for asymptomatic disease [10, 20]. * C. Incorrect because tertiary prevention manages established disease outcomes [10, 22]. * D. Incorrect because anticipatory guidance is a specific developmental counseling technique rather than a main level of prevention [10, 15]. Question 2. In a 66-year-old woman with **schizophrenia**, ordering an **influenza vaccine** is an example of which level of prevention? * A. Primary prevention * B. Secondary prevention * C. Tertiary prevention * D. Health restoration Pause. Answer: A. **Why it is correct**: Vaccines prevent infectious illness before it occurs, making it a **primary prevention** strategy [9, 11, 20, 30]. **Why the other choices are wrong**: * A. Correct. * B. Incorrect because screening detects preclinical disease [10, 20]. * C. Incorrect because tertiary prevention manages chronic established conditions [10, 22]. * D. Incorrect because health restoration is not a standardized level of prevention [9, 10]. Question 3. In a 66-year-old woman with **schizophrenia**, adjusting therapy to enhance system regulation is an example of which level of prevention? * A. Primary prevention * B. Secondary prevention * C. Tertiary prevention * D. Health promotion Pause. Answer: C. **Why it is correct**: Adjusting treatment in an individual with established illness to reduce disease impact is **tertiary prevention** [10, 12, 22, 30]. **Why the other choices are wrong**: * A. Incorrect because primary prevention stops new disease onset [9, 20]. * B. Incorrect because secondary prevention focuses on early screening [10, 20]. * C. Correct. * D. Incorrect because health promotion applies to primary prevention in healthy populations [9, 20]. Question 4. In a 25-year-old with stable **depression** and a strong family history of **type 2 diabetes**, checking a **lipid profile** is an example of which level of prevention? * A. Primary prevention * B. Secondary prevention * C. Tertiary prevention * D. Disease modification Pause. Answer: B. **Why it is correct**: Laboratory screening to detect asymptomatic metabolic abnormalities early is **secondary prevention** [10, 12, 20, 21]. **Why the other choices are wrong**: * A. Incorrect because primary prevention prevents initial disease development [9, 20]. * B. Correct. * C. Incorrect because tertiary prevention manages known, diagnosed conditions [10, 22]. * D. Incorrect because disease modification is not a formal level of health prevention [9, 10]. Question 5. In a 76-year-old man with **post-traumatic stress disorder** (**PTSD**) and **obsessive-compulsive disorder** (**OCD**), ensuring adequate illumination at home is an example of which level of prevention? * A. Primary prevention * B. Secondary prevention * C. Tertiary prevention * D. Environmental rehabilitation Pause. Answer: A. **Why it is correct**: Home lighting modifications prevent falls and injuries before they occur, fulfilling **primary prevention** [9, 13, 20, 21]. **Why the other choices are wrong**: * A. Correct. * B. Incorrect because screening identifies hidden or asymptomatic conditions [10, 20]. * C. Incorrect because tertiary prevention manages established chronic illness [10, 22]. * D. Incorrect because environmental rehabilitation is not a defined level of prevention [9, 10]. Question 6. In a 76-year-old man with **PTSD** and **OCD**, screening for physical, emotional, or financial abuse is an example of which level of prevention? * A. Primary prevention * B. Secondary prevention * C. Tertiary prevention * D. Crisis management Pause. Answer: B. **Why it is correct**: Screening for abuse identifies asymptomatic or undetected harm early to limit further injury, making it **secondary prevention** [10, 13, 20, 21]. **Why the other choices are wrong**: * A. Incorrect because primary prevention avoids the initial risk exposure [9, 20]. * B. Correct. * C. Incorrect because tertiary prevention treats chronic, diagnosed conditions [10, 22]. * D. Incorrect because crisis management is an acute intervention rather than a preventive level [10, 31]. Question 7. Conducting a parenting class for new parents on how to cope with the stressors of having a newborn in the home is an example of which level of prevention? * A. Primary prevention * B. Secondary prevention * C. Tertiary prevention * D. Family therapy Pause. Answer: A. **Why it is correct**: Education provided to new parents to prevent future maladaptive coping or distress is **primary prevention** [9, 13, 20, 29]. **Why the other choices are wrong**: * A. Correct. * B. Incorrect because secondary prevention requires early disease screening [10, 20]. * C. Incorrect because tertiary prevention addresses existing illness [10, 22]. * D. Incorrect because family therapy is a treatment intervention for established dysfunction [10, 32]. Question 8. Administering the **PHQ-9** to all new mothers in a family practice clinic is an example of which level of prevention? * A. Primary prevention * B. Secondary prevention * C. Tertiary prevention * D. Diagnostic evaluation Pause. Answer: B. **Why it is correct**: Standardized screening with the **PHQ-9** in an asymptomatic or general population detects depression in its early state, representing **secondary prevention** [10, 13, 20, 29]. **Why the other choices are wrong**: * A. Incorrect because primary prevention prevents illness before it develops [9, 20]. * B. Correct. * C. Incorrect because tertiary prevention manages established disease [10, 22]. * D. Incorrect because routine screening precedes a formal diagnostic evaluation [10, 33]. Question 9. Conducting a psychoeducation class for family members of people with severe mental illness is an example of which level of prevention? * A. Primary prevention * B. Secondary prevention * C. Tertiary prevention * D. Disease prevention Pause. Answer: C. **Why it is correct**: Providing education to families of individuals with established severe mental illness minimizes disease complications and enhances stability, fulfilling **tertiary prevention** [10, 14, 22, 29]. **Why the other choices are wrong**: * A. Incorrect because primary prevention targets individuals without established disease [9, 20]. * B. Incorrect because secondary prevention focuses on screening asymptomatic individuals [10, 20]. * C. Correct. * D. Incorrect because disease prevention is a general category, not a specific level [9, 10]. Question 10. Adjusting the **lithium** level on a patient with **bipolar disorder** is an example of which level of prevention? * A. Primary prevention * B. Secondary prevention * C. Tertiary prevention * D. Relapse prophylaxis Pause. Answer: C. **Why it is correct**: Pharmacotherapeutic adjustment in an established illness prevents organ toxicity and acute exacerbations, representing **tertiary prevention** [10, 14, 22, 29]. **Why the other choices are wrong**: * A. Incorrect because primary prevention stops initial disease development [9, 20]. * B. Incorrect because secondary prevention involves early screening [10, 20]. * C. Correct. * D. Incorrect because relapse prophylaxis in an active illness falls under tertiary prevention [10, 22]. Question 11. A 35-year-old man with **bipolar disorder** was recently hospitalized for a manic episode. On returning to work as an accountant in a large company, he accesses his company's employee assistance program (**EAP**) to facilitate his return to work. This is an example of which prevention strategy? * A. Primary prevention * B. Secondary prevention * C. Tertiary prevention * D. Anticipatory guidance Pause. Answer: C. **Why it is correct**: Utilizing **EAP** services to restore occupational functioning after hospitalization for an established psychiatric disorder is **tertiary prevention** [10, 14, 15, 22, 23]. **Why the other choices are wrong**: * A. Incorrect because primary prevention prevents initial illness onset [9, 20]. * B. Incorrect because secondary prevention focuses on early screening [10, 20]. * C. Correct. * D. Incorrect because anticipatory guidance prepares individuals for expected developmental milestones rather than post-hospitalization recovery [10, 15]. Next Study Step. Review **Fitzgerald Chapter 2** (**Select Specialty Topics in Psychiatric-Mental Health Practice**) or **Fitzgerald Chapter 9** (**Anxiety Disorders**) to cover complete medical rule-outs, lab baselines, **ECG** monitoring requirements, and differential diagnostic criteria for panic and somatic complaints. * **Why this is the best next step**: It closes the gap on specific medical mimics (such as **hyperthyroidism**, **pheochromocytoma**, and **arrhythmias**) that present with panic and autonomic hyperarousal. * **What confusion it prevents**: It clarifies how to distinguish primary anxiety disorders from secondary medical conditions and psychotropic side effects on board exams. 💡 Would you like to review the diagnostic differential and lab workup for medical mimics of anxiety in Fitzgerald Chapter 2 or Chapter 9 next? Next. End of this drive.